MYBL2

Across TCGA pan-cancer cohorts, MYBL2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MYBL2 data layer compared with 29 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MYBL2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYBL2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

ACC, LUAD, and PRAD are the cancer types where MYBL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	9	view →
PRAD	DFS	Median	All	0.174	0.888	<.001	6	view →
COAD	DFS	Median	All	0.158	0.506	.016	4	view →
SKCM	OS	Median	All	0.683	0.786	.015	4	view →
BLCA	DFS	Median	III,IV	1.000	0.271	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MYBL2–ACC (DFS)

Open the ACC breakdown →